Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2001;9(4):245–247. doi: 10.1155/S1064744901000400

Candida lusitaniae as an Unusual Cause of Recurrent Vaginitis and its Successful Treatment With Intravaginal Boric Acid

Neil S Silverman 1,✉, Margie Morgan 2, W S Nichols 2
PMCID: PMC1784662  PMID: 11916183

Abstract

Increasing use of short-course antifungal therapies in patients with recurrent vulvovaginitis may enable the emergence of less-common, more resistant yeast strains as vaginal pathogens. We report the case of a patient with chronically symptomatic and repeatedly treated vaginal candidiasis whose infection was attributable to Candida lusitaniae, a previously unreported cause of candidal vaginitis .

Full Text

The Full Text of this article is available as a PDF (67.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blinkhorn R. J., Adelstein D., Spagnuolo P. J. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol. 1989 Feb;27(2):236–240. doi: 10.1128/jcm.27.2.236-240.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Horowitz B. J., Giaquinta D., Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 1992 Mar;32(3):248–255. doi: 10.1002/j.1552-4604.1992.tb03833.x. [DOI] [PubMed] [Google Scholar]
  3. Kerridge D., Nicholas R. O. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. J Antimicrob Chemother. 1986 Oct;18 (Suppl B):39–49. doi: 10.1093/jac/18.supplement_b.39. [DOI] [PubMed] [Google Scholar]
  4. Meunier-Carpentier F., Kiehn T. E., Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med. 1981 Sep;71(3):363–370. doi: 10.1016/0002-9343(81)90162-5. [DOI] [PubMed] [Google Scholar]
  5. Minari A., Hachem R., Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis. 2000 Dec 28;32(2):186–190. doi: 10.1086/318473. [DOI] [PubMed] [Google Scholar]
  6. Odds F. C., Webster C. E., Riley V. C., Fisk P. G. Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol. 1987 May;25(1):53–66. doi: 10.1016/0028-2243(87)90092-x. [DOI] [PubMed] [Google Scholar]
  7. Pappagianis D., Collins M. S., Hector R., Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979 Aug;16(2):123–126. doi: 10.1128/aac.16.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Sobel J. D., Chaim W. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis. 1997 Apr;24(4):649–652. doi: 10.1093/clind/24.4.649. [DOI] [PubMed] [Google Scholar]
  9. Sobel J. D. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med. 1986 Dec 4;315(23):1455–1458. doi: 10.1056/NEJM198612043152305. [DOI] [PubMed] [Google Scholar]
  10. Sobel J. D. Vulvovaginitis. When Candida becomes a problem. Dermatol Clin. 1998 Oct;16(4):763-8, xii. doi: 10.1016/s0733-8635(05)70043-7. [DOI] [PubMed] [Google Scholar]
  11. Swate T. E., Weed J. C. Boric acid treatment of vulvovaginal candidiasis. Obstet Gynecol. 1974 Jun;43(6):893–895. [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES